News
Here you’ll find the latest about Myris Therapeutics, our platform, pipeline and technologies.
Myris Therapeutics is Developing Ultra-High DAR ADCs to Enable Novel Precision Medicine Treatments for Cancer
Myris Therapeutics emerges from stealth to announce new name and strategic focus Proprietary polymer chemistry enables ultra-high drug to antibody ratios of 50 - 100 and new chemical space for precision targeted ADC payloads PITTSBURGH, Feb. 20,...
BioHybrid Solutions Holdings, Inc. Announces Expansion of its Drug Development Leadership
Pittsburgh, PA. June 02, 2023 Biohybrid Solutions Holdings, Inc. (BHS), is a biotechnology company using advanced polymer technologies to address outstanding challenges in the development of biologic drugs. BHS’ NanoArmor® technology balances...
BioHybrid Solutions Holdings, Inc. Appoints Mark Murcko as Board Member
Pittsburgh, PA. August 09, 2022 We are excited to announce the appointment of Mark Murcko, Ph.D., as our newest Board Member. Mark brings over three decades of industry experience, having been at the center of many transformational biotech efforts...
BioHybrid Solutions™ announces the formation of its Holdings Corporation and Subsidiaries
Pittsburgh, PA. May 4th, 2022 We are excited to announce the strategic re-structuring of BioHybrid Solutions, LLC (BHS, LLC). BHS, LLC is now a wholly-owned subsidiary of BioHybrid Solutions Holdings, Inc. (BHSH, Inc.). On the heels of this...
BioHybrid Solutions™ Announces Jean Pineault as President and Chief Executive Officer
Pittsburgh, PA, January 5th, 2022– BioHybrid Solutions™ (BHS) is pleased to announce the appointment of Jean Pineault as its new President and Chief Executive Officer effective immediately. Jean, brings a wealth of leadership, experience, and...
BioHybrid Solutions™ Awarded $30M Contract by the US Dept. of Defense
™Funding from the US Department of Defense will advance the technology towards approval for the protection of America’s military (PITTSBURGH, PA) Dec. 4 BioHybrid Solutions, LLC (BHS), a Pittsburgh-based protein engineering company, announced today...